Regulatory FDA approves Enhertu for two HER2-positive early breast cancer indications Pharmaceutical TechnologyThe FDA has approved Daiichi Sankyo and AstraZeneca's Enhertu for two new indications in HER2-positive early breast cancer.OncologyRead full story pharminent May 18, 2026 (Last updated: May 18, 2026) Pharmaceutical Technology The FDA has approved Daiichi Sankyo and AstraZeneca’s Enhertu for two new indications in HER2-positive early breast cancer. Oncology Read full story Post navigation Previous: Arna Pharma and Slate Run complete JV for new US companyNext: Cellbxhealth partners with AdventHealth on CTCbased monitoring in two major cancer studies Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
